Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment

医学 药代动力学 泌尿科 药理学 不利影响 加药 耐受性 相伴的 肾功能 内科学 置信区间 内皮素受体拮抗剂 内皮素受体 受体
作者
Patricia N. Sidharta,Ivan Ulč,Jasper Dingemanse
出处
期刊:Clinical Drug Investigation [Adis, Springer Healthcare]
卷期号:39 (11): 1117-1123 被引量:18
标识
DOI:10.1007/s40261-019-00837-x
摘要

The orally active dual endothelin receptor antagonist aprocitentan targets a novel pathway in the treatment of hypertension and could be a key player in the treatment of salt/volume-dependent hypertension. Its pharmacokinetic profile supports a once-daily dosing strategy. As hypertensive patients may also experience concomitant renal disease, the objectives of this study were to evaluate the pharmacokinetics and tolerability of aprocitentan in subjects with severe renal function impairment (SRFI) and compare these with matched healthy subjects. In this open-label, single-center, phase 1 study (NCT03165071) eight subjects with SRFI (mean estimated glomerular filtration rate [eGFR] 21.9 mL/min/1.73 m2) and eight healthy subjects (mean eGFR 94.9 mL/min/1.73 m2) received a single dose of 50 mg of aprocitentan followed by an observation period of up to 17 days. Plasma pharmacokinetic parameters of aprocitentan were derived by noncompartmental analysis of the plasma concentration-time profiles. Differences in pharmacokinetic parameters were explored using geometric means ratio (GMR) and 90% confidence intervals (CIs) with SRFI subjects as test group and healthy subjects as reference group. Safety and tolerability evaluations included adverse events (AEs), electrocardiograms, vital signs, and clinical laboratory tests. All 16 subjects received aprocitentan and completed the study. The pharmacokinetics of aprocitentan were similar in SRFI and healthy subjects with maximum plasma concentrations reached at 7.6 h and 5.0 h, respectively. Maximum plasma concentrations did not differ as indicated by a GMR (90% CI) of 1.04 (0.85–1.28). Due to a slightly lower observed clearance in SRFI subjects, half-life was longer (53.2 h compared to 47.4 h in healthy subjects), while exposure expressed as area under the curve was 34% higher (GMR 90% CI 1.13–1.58). There were no differences in plasma protein binding (> 99% bound). Aprocitentan was well tolerated in subjects with SRFI with no notable difference compared to healthy subjects. Based on these single-dose results, subjects with mild, moderate, or severe renal function can be included in clinical studies without the need for dose adjustment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
明理栾完成签到,获得积分10
刚刚
1秒前
嘉的科研完成签到 ,获得积分10
1秒前
田様应助比巴卜采纳,获得10
2秒前
张薇完成签到,获得积分10
2秒前
2秒前
内敛诚C完成签到 ,获得积分10
3秒前
4秒前
4秒前
champagnefeng发布了新的文献求助10
4秒前
秋不落棠发布了新的文献求助10
5秒前
宛宛发布了新的文献求助10
5秒前
思源应助扣欧克泥采纳,获得10
5秒前
pengzzZZ完成签到,获得积分10
5秒前
5秒前
6秒前
墨宁发布了新的文献求助10
6秒前
明理栾发布了新的文献求助10
7秒前
7秒前
8秒前
欢呼的方盒完成签到,获得积分10
8秒前
qq发布了新的文献求助10
8秒前
9秒前
huayi发布了新的文献求助10
9秒前
黄黄发布了新的文献求助10
10秒前
ding应助顺利的雁梅采纳,获得10
10秒前
垃圾桶发布了新的文献求助10
10秒前
10秒前
林森发布了新的文献求助200
12秒前
比巴卜发布了新的文献求助10
12秒前
13秒前
杉杉发布了新的文献求助10
13秒前
黑粉头头发布了新的文献求助10
13秒前
科目三应助明理栾采纳,获得10
13秒前
哈皮发布了新的文献求助10
14秒前
潇洒愚志发布了新的文献求助10
15秒前
17秒前
入门的橙橙完成签到 ,获得积分10
18秒前
尔尔发布了新的文献求助30
18秒前
红叶完成签到,获得积分10
18秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Toward a Combinatorial Approach for the Prediction of IgG Half-Life and Clearance 500
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969940
求助须知:如何正确求助?哪些是违规求助? 3514642
关于积分的说明 11175298
捐赠科研通 3249947
什么是DOI,文献DOI怎么找? 1795178
邀请新用户注册赠送积分活动 875617
科研通“疑难数据库(出版商)”最低求助积分说明 804891